InvestmentJun 17, 2026, 04:30 PM
Legend Biotech Commences $225M Public Offering of ADSs
AI Summary
Legend Biotech Corporation has announced the commencement of an underwritten public offering to sell $225 million of American Depositary Shares (ADSs). The company will offer all ADSs, with underwriters holding a 30-day option to purchase an additional 15% of the ADSs sold. The offering is being managed by Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities as joint book-running managers.
Key Highlights
- Legend Biotech commenced an underwritten public offering of American Depositary Shares (ADSs).
- The offering aims to raise $225 million.
- All ADSs will be offered by Legend Biotech.
- Underwriters have a 30-day option to purchase up to an additional 15% of ADSs.
- Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are joint book-running managers.
Price Impact
More from LEGN